Skip to main content
Erschienen in:

05.01.2022 | Pancreatic Tumors

Landmark Series: Importance of Pancreatic Resection Margins

verfasst von: Mihir M. Shah, MD, Jashodeep Datta, MD, Nipun B. Merchant, MD, David A. Kooby, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

An important goal of cancer surgery is to achieve negative surgical margins and remove all disease completely. For pancreatic neoplasms, microscopic margins may remain positive despite gross removal of the palpable mass, and surgeons must then consider extending resection, even to the point of completion pancreatectomy, an option that renders the patient with significant adverse effects related to exocrine and endocrine insufficiency. Counterintuitively, extending resection to ensure clear margins may not improve patient outcome. Furthermore, the goal of improving survival by extending the resection may not be achieved, as an initial positive margin may indicate more aggressive underlying tumor biology. There is a growing body of literature on this topic, and this landmark series review will examine the key publications that guide our management for resection of pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasms, and pancreatic neuroendocrine tumors.
Literatur
1.
Zurück zum Zitat Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55(3):277–83.PubMedCrossRef Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55(3):277–83.PubMedCrossRef
2.
Zurück zum Zitat Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;254(2):311–9.PubMedCrossRef Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;254(2):311–9.PubMedCrossRef
3.
Zurück zum Zitat Jamieson NB, Foulis AK, Oien KA, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010;251(6):1003–10.PubMedCrossRef Jamieson NB, Foulis AK, Oien KA, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010;251(6):1003–10.PubMedCrossRef
4.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
6.
Zurück zum Zitat Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.PubMedCrossRef Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.PubMedCrossRef
7.
Zurück zum Zitat Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.PubMedCrossRef Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.PubMedCrossRef
9.
Zurück zum Zitat DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol. 1999;10(Suppl 4):140–2.PubMedCrossRef DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol. 1999;10(Suppl 4):140–2.PubMedCrossRef
10.
Zurück zum Zitat Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6(5):597–612.PubMedCrossRef Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6(5):597–612.PubMedCrossRef
11.
Zurück zum Zitat Adsay NV, Basturk O, Saka B, et al. Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors. Am J Surg Pathol. 2014;38(4):480–93.PubMedPubMedCentralCrossRef Adsay NV, Basturk O, Saka B, et al. Whipple made simple for surgical pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy specimens for a more practical and accurate evaluation of pancreatic, distal common bile duct, and ampullary tumors. Am J Surg Pathol. 2014;38(4):480–93.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232–7.PubMedCrossRef Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232–7.PubMedCrossRef
13.
Zurück zum Zitat Hernandez J, Mullinax J, Clark W, et al. Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Surg. 2009;250(1):76–80.PubMedCrossRef Hernandez J, Mullinax J, Clark W, et al. Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins. Ann Surg. 2009;250(1):76–80.PubMedCrossRef
14.
Zurück zum Zitat Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.PubMedCrossRef Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.PubMedCrossRef
15.
Zurück zum Zitat Chandrasegaram MD, Goldstein D, Simes J, et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg. 2015;102(12):1459–72.PubMedCrossRef Chandrasegaram MD, Goldstein D, Simes J, et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg. 2015;102(12):1459–72.PubMedCrossRef
16.
Zurück zum Zitat Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(3):520–9.PubMedCrossRef Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(3):520–9.PubMedCrossRef
17.
Zurück zum Zitat Kooby DA, Lad NL, Squires MH 3rd, et al. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Ann Surg. 2014;260(3):494–501 (discussion 493–501).PubMedCrossRef Kooby DA, Lad NL, Squires MH 3rd, et al. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Ann Surg. 2014;260(3):494–501 (discussion 493–501).PubMedCrossRef
18.
Zurück zum Zitat Zhang B, Lee GC, Qadan M, et al. Revision of pancreatic neck margins based on intraoperative frozen section analysis is associated with improved survival in patients undergoing pancreatectomy for ductal adenocarcinoma. Ann Surg. 2021;274(2):e134–42.PubMedCrossRef Zhang B, Lee GC, Qadan M, et al. Revision of pancreatic neck margins based on intraoperative frozen section analysis is associated with improved survival in patients undergoing pancreatectomy for ductal adenocarcinoma. Ann Surg. 2021;274(2):e134–42.PubMedCrossRef
19.
Zurück zum Zitat Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–68.PubMedPubMedCentralCrossRef Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–68.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Dillhoff M, Yates R, Wall K, et al. Intraoperative assessment of pancreatic neck margin at the time of pancreaticoduodenectomy increases likelihood of margin-negative resection in patients with pancreatic cancer. J Gastrointest Surg. 2009;13(5):825–30.PubMedPubMedCentralCrossRef Dillhoff M, Yates R, Wall K, et al. Intraoperative assessment of pancreatic neck margin at the time of pancreaticoduodenectomy increases likelihood of margin-negative resection in patients with pancreatic cancer. J Gastrointest Surg. 2009;13(5):825–30.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Lad NL, Squires MH, Maithel SK, et al. Is it time to stop checking frozen section neck margins during pancreaticoduodenectomy? Ann Surg Oncol. 2013;20(11):3626–33.PubMedCrossRef Lad NL, Squires MH, Maithel SK, et al. Is it time to stop checking frozen section neck margins during pancreaticoduodenectomy? Ann Surg Oncol. 2013;20(11):3626–33.PubMedCrossRef
22.
Zurück zum Zitat Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010;116(14):3369–77.PubMedCrossRef Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010;116(14):3369–77.PubMedCrossRef
23.
Zurück zum Zitat Mathur A, Ross SB, Luberice K, et al. Margin status impacts survival after pancreaticoduodenectomy but negative margins should not be pursued. Am Surg. 2014;80(4):353–60.PubMedCrossRef Mathur A, Ross SB, Luberice K, et al. Margin status impacts survival after pancreaticoduodenectomy but negative margins should not be pursued. Am Surg. 2014;80(4):353–60.PubMedCrossRef
24.
Zurück zum Zitat Fatima J, Schnelldorfer T, Barton J, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145(2):167–72.PubMedCrossRef Fatima J, Schnelldorfer T, Barton J, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145(2):167–72.PubMedCrossRef
25.
Zurück zum Zitat Nitschke P, Volk A, Welsch T, et al. Impact of intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: a single-center experience with 483 patients. Ann Surg. 2017;265(6):1219–25.PubMedCrossRef Nitschke P, Volk A, Welsch T, et al. Impact of intraoperative re-resection to achieve R0 status on survival in patients with pancreatic cancer: a single-center experience with 483 patients. Ann Surg. 2017;265(6):1219–25.PubMedCrossRef
26.
Zurück zum Zitat Greco SH, August DA, Shah MM, et al. Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: an analysis of the National Cancer Database. Surg Open Sci. 2021;3:22–8.PubMedCrossRef Greco SH, August DA, Shah MM, et al. Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: an analysis of the National Cancer Database. Surg Open Sci. 2021;3:22–8.PubMedCrossRef
27.
Zurück zum Zitat Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.PubMedCrossRef Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.PubMedCrossRef
28.
Zurück zum Zitat Ahmad SA, Duong M, Sohal DPS, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus Gemcitabine/Nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272(3):481–6.PubMedCrossRef Ahmad SA, Duong M, Sohal DPS, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus Gemcitabine/Nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272(3):481–6.PubMedCrossRef
29.
Zurück zum Zitat Maeda S, Moore AM, Yohanathan L, et al. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Surgery. 2020;167(5):803–11.PubMedCrossRef Maeda S, Moore AM, Yohanathan L, et al. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Surgery. 2020;167(5):803–11.PubMedCrossRef
30.
31.
Zurück zum Zitat Schmocker RK, Delitto D, Wright MJ, et al. Impact of margin status on survival in patients with pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy. J Am Coll Surg. 2021;232(4):405–13.PubMedCrossRef Schmocker RK, Delitto D, Wright MJ, et al. Impact of margin status on survival in patients with pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy. J Am Coll Surg. 2021;232(4):405–13.PubMedCrossRef
32.
Zurück zum Zitat Datta J, Willobee BA, Ryon EL, et al. Contemporary reappraisal of intraoperative neck margin assessment during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a review. JAMA Surg. 2021;156(5):489–95.PubMedCrossRef Datta J, Willobee BA, Ryon EL, et al. Contemporary reappraisal of intraoperative neck margin assessment during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a review. JAMA Surg. 2021;156(5):489–95.PubMedCrossRef
33.
Zurück zum Zitat Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651–60.PubMedCrossRef Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651–60.PubMedCrossRef
34.
Zurück zum Zitat Gebauer F, Tachezy M, Vashist YK, et al. Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? World J Surg. 2015;39(2):493–9.PubMedCrossRef Gebauer F, Tachezy M, Vashist YK, et al. Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? World J Surg. 2015;39(2):493–9.PubMedCrossRef
35.
Zurück zum Zitat Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003;133(5):521–7.PubMedCrossRef Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003;133(5):521–7.PubMedCrossRef
36.
Zurück zum Zitat Cao F, Li J, Li A, Li F. Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer: a systemic review and meta-analysis. BMC Surg. 2017;17(1):67.PubMedPubMedCentralCrossRef Cao F, Li J, Li A, Li F. Radical antegrade modular pancreatosplenectomy versus standard procedure in the treatment of left-sided pancreatic cancer: a systemic review and meta-analysis. BMC Surg. 2017;17(1):67.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Zhou Q, Fengwei G, Gong J, et al. Assessement of postoperative long-term survival quality and complications associated with radical antegrade modular pancreatosplenectomy and distal pancreatectomy: a meta-analysis and systematic review. BMC Surg. 2019;19(1):12.PubMedPubMedCentralCrossRef Zhou Q, Fengwei G, Gong J, et al. Assessement of postoperative long-term survival quality and complications associated with radical antegrade modular pancreatosplenectomy and distal pancreatectomy: a meta-analysis and systematic review. BMC Surg. 2019;19(1):12.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Huo Z, Zhai S, Wang Y, et al. Comparison of radical antegrade modular pancreatosplenectomy with standard retrograde pancreatosplenectomy for left-sided pancreatic cancer: a meta-analysis and experience of a single center. Med Sci Monit. 2019;25:4590–601.PubMedPubMedCentralCrossRef Huo Z, Zhai S, Wang Y, et al. Comparison of radical antegrade modular pancreatosplenectomy with standard retrograde pancreatosplenectomy for left-sided pancreatic cancer: a meta-analysis and experience of a single center. Med Sci Monit. 2019;25:4590–601.PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Magge D, Gooding W, Choudry H, et al. Comparative effectiveness of minimally invasive and open distal pancreatectomy for ductal adenocarcinoma. JAMA Surg. 2013;148(6):525–31.PubMedCrossRef Magge D, Gooding W, Choudry H, et al. Comparative effectiveness of minimally invasive and open distal pancreatectomy for ductal adenocarcinoma. JAMA Surg. 2013;148(6):525–31.PubMedCrossRef
40.
Zurück zum Zitat Yang DJ, Xiong JJ, Lu HM, et al. The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Sci Rep. 2019;9(1):1159.PubMedPubMedCentralCrossRef Yang DJ, Xiong JJ, Lu HM, et al. The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Sci Rep. 2019;9(1):1159.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat van Hilst J, Korrel M, de Rooij T, et al. Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol. 2019;45(5):719–27.PubMedCrossRef van Hilst J, Korrel M, de Rooij T, et al. Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol. 2019;45(5):719–27.PubMedCrossRef
42.
Zurück zum Zitat van Hilst J, de Rooij T, Klompmaker S, et al. Minimally invasive versus open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): a Pan-European Propensity Score matched study. Ann Surg. 2019;269(1):10–7.PubMedCrossRef van Hilst J, de Rooij T, Klompmaker S, et al. Minimally invasive versus open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): a Pan-European Propensity Score matched study. Ann Surg. 2019;269(1):10–7.PubMedCrossRef
43.
Zurück zum Zitat Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53.PubMedCrossRef Tanaka M, Fernandez-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–53.PubMedCrossRef
44.
Zurück zum Zitat Marchegiani G, Mino-Kenudson M, Sahora K, et al. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg. 2015;261(5):976–83.PubMedCrossRef Marchegiani G, Mino-Kenudson M, Sahora K, et al. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann Surg. 2015;261(5):976–83.PubMedCrossRef
45.
Zurück zum Zitat Couvelard A, Sauvanet A, Kianmanesh R, et al. Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation. Ann Surg. 2005;242(6):774–8 (discussion 778–780).PubMedPubMedCentralCrossRef Couvelard A, Sauvanet A, Kianmanesh R, et al. Frozen sectioning of the pancreatic cut surface during resection of intraductal papillary mucinous neoplasms of the pancreas is useful and reliable: a prospective evaluation. Ann Surg. 2005;242(6):774–8 (discussion 778–780).PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002;123(5):1500–7.PubMedCrossRef Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002;123(5):1500–7.PubMedCrossRef
47.
Zurück zum Zitat Farnell MB. Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. J Gastrointest Surg. 2008;12(3):414–6.PubMedCrossRef Farnell MB. Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. J Gastrointest Surg. 2008;12(3):414–6.PubMedCrossRef
48.
Zurück zum Zitat Fujii T, Kato K, Kodera Y, et al. Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery. 2010;148(2):285–90.PubMedCrossRef Fujii T, Kato K, Kodera Y, et al. Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. Surgery. 2010;148(2):285–90.PubMedCrossRef
49.
Zurück zum Zitat Jang JY, Kim SW, Ahn YJ, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol. 2005;12(2):124–32.PubMedCrossRef Jang JY, Kim SW, Ahn YJ, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol. 2005;12(2):124–32.PubMedCrossRef
50.
Zurück zum Zitat White R, D’Angelica M, Katabi N, et al. Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg. 2007;204(5):987–93 (discussion 985–993).PubMedCrossRef White R, D’Angelica M, Katabi N, et al. Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg. 2007;204(5):987–93 (discussion 985–993).PubMedCrossRef
51.
Zurück zum Zitat Crippa S, Pergolini I, Rubini C, et al. Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms. Surgery. 2016;159(4):1041–9.PubMedCrossRef Crippa S, Pergolini I, Rubini C, et al. Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms. Surgery. 2016;159(4):1041–9.PubMedCrossRef
52.
Zurück zum Zitat Dhar VK, Merchant NB, Patel SH, et al. Does surgical margin impact recurrence in noninvasive intraductal papillary mucinous neoplasms? A multi-institutional study. Ann Surg. 2018;268(3):469–78.PubMedCrossRef Dhar VK, Merchant NB, Patel SH, et al. Does surgical margin impact recurrence in noninvasive intraductal papillary mucinous neoplasms? A multi-institutional study. Ann Surg. 2018;268(3):469–78.PubMedCrossRef
53.
Zurück zum Zitat Hirono S, Shimizu Y, Ohtsuka T, et al. Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol. 2020;55(1):86–99.PubMedCrossRef Hirono S, Shimizu Y, Ohtsuka T, et al. Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol. 2020;55(1):86–99.PubMedCrossRef
54.
Zurück zum Zitat He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216(4):657–65 (discussion 657–665).PubMedPubMedCentralCrossRef He J, Cameron JL, Ahuja N, et al. Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm? J Am Coll Surg. 2013;216(4):657–65 (discussion 657–665).PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Kang MJ, Jang JY, Lee KB, Chang YR, Kwon W, Kim SW. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg. 2014;260(2):356–63.PubMedCrossRef Kang MJ, Jang JY, Lee KB, Chang YR, Kwon W, Kim SW. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg. 2014;260(2):356–63.PubMedCrossRef
56.
Zurück zum Zitat Frankel TL, LaFemina J, Bamboat ZM, et al. Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms. HPB (Oxford). 2013;15(10):814–21.CrossRef Frankel TL, LaFemina J, Bamboat ZM, et al. Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms. HPB (Oxford). 2013;15(10):814–21.CrossRef
57.
Zurück zum Zitat Kasumova GG, Tabatabaie O, Eskander MF, Tadikonda A, Ng SC, Tseng JF. National rise of primary pancreatic carcinoid tumors: comparison to functional and nonfunctional pancreatic neuroendocrine tumors. J Am Coll Surg. 2017;224(6):1057–64.PubMedCrossRef Kasumova GG, Tabatabaie O, Eskander MF, Tadikonda A, Ng SC, Tseng JF. National rise of primary pancreatic carcinoid tumors: comparison to functional and nonfunctional pancreatic neuroendocrine tumors. J Am Coll Surg. 2017;224(6):1057–64.PubMedCrossRef
58.
Zurück zum Zitat Partelli S, Giannone F, Schiavo Lena M, et al. Is the real prevalence of pancreatic neuroendocrine tumors underestimated? A retrospective study on a large series of pancreatic specimens. Neuroendocrinology. 2019;109(2):165–70.PubMedCrossRef Partelli S, Giannone F, Schiavo Lena M, et al. Is the real prevalence of pancreatic neuroendocrine tumors underestimated? A retrospective study on a large series of pancreatic specimens. Neuroendocrinology. 2019;109(2):165–70.PubMedCrossRef
59.
Zurück zum Zitat Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1):1–18.CrossRef Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1):1–18.CrossRef
60.
Zurück zum Zitat Jilesen AP, van Eijck CH, Busch OR, van Gulik TM, Gouma DJ, van Dijkum EJ. Postoperative outcomes of enucleation and standard resections in patients with a pancreatic neuroendocrine tumor. World J Surg. 2016;40(3):715–28.PubMedCrossRef Jilesen AP, van Eijck CH, Busch OR, van Gulik TM, Gouma DJ, van Dijkum EJ. Postoperative outcomes of enucleation and standard resections in patients with a pancreatic neuroendocrine tumor. World J Surg. 2016;40(3):715–28.PubMedCrossRef
61.
Zurück zum Zitat Zhang XF, Wu Z, Cloyd J, et al. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: results from the US Neuroendocrine Tumor Study Group. Surgery. 2019;165(3):548–56.PubMedCrossRef Zhang XF, Wu Z, Cloyd J, et al. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: results from the US Neuroendocrine Tumor Study Group. Surgery. 2019;165(3):548–56.PubMedCrossRef
Metadaten
Titel
Landmark Series: Importance of Pancreatic Resection Margins
verfasst von
Mihir M. Shah, MD
Jashodeep Datta, MD
Nipun B. Merchant, MD
David A. Kooby, MD
Publikationsdatum
05.01.2022
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2022
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-11168-7

Neu im Fachgebiet Chirurgie

Nackenschmerzen nach Bandscheibenvorfall: Muskeltraining hilft!

Bei hartnäckigen Schmerzen aufgrund einer zervikalen Radikulopathie schlägt ein Team der Universität Istanbul vor, lokale Steroidinjektionen mit einem speziellen Trainingsprogramm zur Stabilisierung der Nackenmuskulatur zu kombinieren.

US-Team empfiehlt Gastropexie nach Hiatushernien-Op.

Zur Vermeidung von Rezidiven nach Reparatur einer paraösophagealen Hiatushernie sollte einem US-Team zufolge der Magen bei der Op. routinemäßig an der Bauchwand fixiert werden. Das Ergebnis einer randomisierten Studie scheint dafür zu sprechen.

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.